Skip to Content

Mark Gladwin, MD

  • Associate Vice Chancellor for Science Strategy, University of Pittsburgh
  • Chair, Department of Medicine, University of Pittsburgh School of Medicine
  • Director of the Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute (VMI)
  • Co-director/research of the UPMC Heart and Vascular Institute (HVI)

An expert in pulmonary hypertension and sickle cell disease, Dr. Gladwin among many other recent research projects has been the principal investigator on the multi-center clinical trials Walk-PHASST (Pulmonary Hypertension and Sickle Sildenafil Therapy Trial) and DeNOVO (Delivery of NO for Vaso-Occlusive pain crisis in sickle cell disease).  He has served as a principal or associate investigator on more than 25 clinical trials.

Since 1998, his research activities have led to more than 200 published, peer-reviewed manuscripts. Dr. Gladwin discovered that pulmonary hypertension occurs in more than 10 percent of patients with sickle cell disease, making it a major cause of mortality in this population.

Dr. Gladwin received his medical degree from the University of Miami Honors Program in Medical Education in 1991. After completing his internship and chief residency at the Oregon Health Sciences University in Portland, he joined the National Institutes of Health (NIH) in 1995 as a critical care fellow. After completing a clinical fellowship in pulmonary medicine at the University of Washington in Seattle, Dr. Gladwin served as chief of the Pulmonary and Vascular Medicine Branch within the National Heart, Lung and Blood Institute, an arm of the NIH.